Alignment Healthcare (NASDAQ:ALHC) Insider Robert Scavo Sells 11,285 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Robert Scavo sold 11,285 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total transaction of $201,324.40. Following the transaction, the insider directly owned 487,685 shares of the company’s stock, valued at $8,700,300.40. This represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alignment Healthcare Price Performance

Shares of ALHC opened at $17.96 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. The stock’s 50 day moving average is $20.51 and its two-hundred day moving average is $18.78. Alignment Healthcare, Inc. has a twelve month low of $11.63 and a twelve month high of $23.87. The firm has a market capitalization of $3.67 billion, a PE ratio of -1,794.01, a P/E/G ratio of 2.66 and a beta of 1.18.

Alignment Healthcare (NASDAQ:ALHC) last issued its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business posted ($0.16) EPS. The company’s revenue for the quarter was up 44.4% on a year-over-year basis. Research analysts anticipate that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ALHC. JPMorgan Chase & Co. upped their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Wall Street Zen cut shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. KeyCorp reissued an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a report on Thursday, January 22nd. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a research report on Friday, January 30th. Finally, UBS Group lifted their price target on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $24.56.

Institutional Investors Weigh In On Alignment Healthcare

A number of large investors have recently added to or reduced their stakes in ALHC. Teacher Retirement System of Texas increased its position in Alignment Healthcare by 85.8% during the third quarter. Teacher Retirement System of Texas now owns 102,827 shares of the company’s stock worth $1,794,000 after buying an additional 47,472 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Alignment Healthcare in the third quarter valued at $3,499,000. Inspire Investing LLC purchased a new stake in shares of Alignment Healthcare in the third quarter valued at $1,129,000. Cinctive Capital Management LP acquired a new stake in shares of Alignment Healthcare during the third quarter valued at $3,814,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Alignment Healthcare by 32.9% during the second quarter. Ameritas Investment Partners Inc. now owns 13,031 shares of the company’s stock valued at $182,000 after acquiring an additional 3,225 shares during the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Analyst optimism — several brokerages have raised price targets and maintained Overweight/Buy views (Piper Sandler, KeyCorp, JPMorgan, Robert W. Baird), supporting upside expectations and a consensus “Moderate Buy” rating. MarketBeat ALHC Analyst Coverage
• Positive Sentiment: Recent earnings beat — Alignment reported Q4 revenue of ~$1.01B and EPS of ($0.05), topping consensus (revenue ~ $1.00B; EPS -$0.15), showing strong revenue growth (Y/Y +44%). This fundamental print remains supportive. Earnings Summary
• Neutral Sentiment: Zacks comparison piece — a valuation/comparison article contrasts ALHC with BrightSpring (BTSG); useful context for long-term investors but not an immediate market catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data appears erroneous (shows 0 shares / NaN changes). Do not treat published short-interest figures as evidence of rising short pressure until exchanges correct the data.
• Negative Sentiment: CEO sale — John E. Kao sold 73,046 shares at an average $17.84 (~$1.30M), trimming his stake ~3.93%. This large insider sale is a near-term negative signal for sentiment. SEC Filing — Kao
• Negative Sentiment: Multiple senior insider sales on Mar 18 — President Dawn C. Maroney (36,749 shares, $17.84; also several prior sales in March/Jan), COO Sebastian Burzacchi (15,361 shares, $17.84), Christopher J. Joyce (25,125 shares, $17.84), Hyong Kim (18,404 shares, $17.84), Andreas P. Wagner (12,000 @ $17.84 and 11,602 @ $18.22), and Robert L. Scavo (11,285 shares, $17.84). These clustered disposals by senior management create headline risk and downward pressure. Representative filings: Maroney — Maroney SEC Filing; Joyce — Joyce SEC Filing; Wagner filings — Wagner SEC Filing

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.